Overall rank by patents
#4,166
Across all tracked assignees
USPTO PatentsView assignee record - 86 granted patents across 41 technology areas, active 2015–2025. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: C08L (COMPOSITIONS OF MACROMOLECULAR COMPOUNDS).
The verdict
Novamont holds 86 US patents across 41 technology areas, rank #4,166 of 50,000 tracked assignees.
Novamont S.p.a. has been granted 86 US utility patents between 2015 and 2025, placing Novamont S.p.a. at rank #4,166 across all assignees tracked by PlainPatent. This portfolio spans 41 distinct Cooperative Patent Classification (CPC) subclasses, averaging 17.8 claims per patent with primary concentration in C08L (COMPOSITIONS OF MACROMOLECULAR COMPOUNDS). As a Foreign Corporation, Novamont S.p.a. is one of the more focused assignees in the PatentsView dataset. By volume, Novamont sits between Mochida Pharmaceutical Co., Ltd. (86 patents, rank #4,162) and Radian Memory Systems, ILLC (86 patents, rank #4,170) - the closest US assignees by grant volume. The composite Innovation Score of 53.5/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.
Filing cadence tells the strategic story. Between 2020 and 2025 the company received 47 grants, compared with 39 in the 2015–2019 window, a +21% shift in five-year velocity. Steady filing volume suggests sustained innovation without dramatic pivots. The Foreign Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.
Claim depth and technology breadth together indicate competitive posture. Novamont S.p.a.'s 17.8 average claims per patent sits within the typical range for solid legal coverage without excessive prosecution cost, while a multi-domain presence across 41 subclasses balances depth with breadth. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark Novamont S.p.a. against peers pursuing similar technology classes.
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
MOCHIDA PHARMACEUTICAL CO., LTD.
86 patents
Means Industries, Inc.
86 patents
National Presto Industries, Inc.
86 patents
Neturen Co., Ltd.
86 patents
PROTEGRITY CORPORATION
86 patents
Plastic Omnium Advanced Innovation and Research
86 patents
ROBE lighting s.r.o.
86 patents
Radian Memory Systems, ILLC
86 patents
Novamont S.p.A.
86 patents
What this shows Novamont holds 86 patents at rank #4,166, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
By rank, the assignees closest to #4,166 in granted patent volume.
Other assignees with the most granted patents in Novamont's primary technology class.
Novamont's Innovation Score vs. every tracked assignee
Composite of portfolio volume, filing velocity, technology breadth, and claim depth (0–100)
54 Top 9% higher than 91% of 50,000 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2015 | 4 | 4.7% |
| 2016 | 7 | 8.1% |
| 2017 | 5 | 5.8% |
| 2018 | 12 | 14.0% |
| 2019 | 11 | 12.8% |
| 2020 | 14 | 16.3% |
| 2021 | 7 | 8.1% |
| 2022 | 13 | 15.1% |
| 2023 | 6 | 7.0% |
| 2024 | 4 | 4.7% |
| 2025 | 3 | 3.5% |
Top 15 of 41 technology areas
Overall rank by patents
#4,166
Across all tracked assignees
53.5 out of 100
How to use this portfolio
Novamont's 86 grants land it in the top 9% by Innovation Score, but volume alone doesn't tell you where the strength sits.
Patent counts and the Innovation Score measure patenting activity, not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.